1
|
Bjørnsdottir I, Lotz R, Lindmark B, Hood S, Christensen JK. Meeting Report: DMDG Peptide and Oligonucleotide ADME Workshop 2024. Xenobiotica 2025:1-10. [PMID: 40390543 DOI: 10.1080/00498254.2025.2506702] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2025] [Revised: 05/09/2025] [Accepted: 05/12/2025] [Indexed: 05/21/2025]
Abstract
Challenges within peptide and oligonucleotide ADME (absorption, distribution, metabolism and elimination) and scientific ideas on how to solve them were presented and discussed at the DMDG (Drug Metabolism and Discussion Group) Peptide and Oligonucleotide ADME Workshop 2024 (1st September 2024). This meeting report summarises the presentations and discussions from this workshop.The following topics were covered:Metabolism of conjugated peptides & proteinsStrategies for increased metabolic stability of peptidesIQ's take on metabolism & excretion studies for peptidesDMPK challenges related to oligonucleotides during developmentImaging of oligonucleotidesIdentification of extrahepatic targets of oligonucleotidesIn vitro systems for metabolism studies of oligonucleotidesNovel hybridization LC-MS/MS approach for quantitative analysis of oligonucleotidesPKPD, PBPK & modelling.
Collapse
Affiliation(s)
| | - Ralf Lotz
- Development NCE, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
| | - Bo Lindmark
- Drug Metabolism and Pharmacokinetics, Early Research and Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
| | - Steve Hood
- Oligo ADME Strategy, DMPK, GlaxoSmithKline, Stevenage, United Kingdom
| | | |
Collapse
|
2
|
Ly M, Diaz-Garcia S, Roscoe N, Ushach I, Hong Z, França M, Schaffer S, Yang TY, Marella M, Marsboom G, Klein D, Grossman TR, Carreira V, Ollmann M. Multiplexed siRNA Immunoassay Unveils Spatial and Quantitative Dimensions of siRNA Function, Abundance, and Localization In Vitro and In Vivo. Toxicol Pathol 2025:1926233241311539. [PMID: 39829074 DOI: 10.1177/01926233241311539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2025]
Abstract
Small interfering RNAs (siRNAs) have been successfully used as therapeutics to silence disease-causing genes when conjugated to ligands or formulated in lipid nanoparticles to target relevant cell types for efficacy while sparing other cells for safety. To support the development of new methods for delivery of siRNA therapeutics, we developed and characterized a panel of antibodies generated against chemically modified nucleotides used in therapeutic siRNA molecules, identifying a monoclonal antibody that detects a broad range of siRNA representing distinct sequences and modification patterns. By integrating this anti-siRNA antibody with additional reagents, we created a multiplex siRNA immunoassay that simultaneously quantifies siRNA uptake, trafficking, and silencing activity. Using immunohistochemistry (IHC), we applied our method on tissues from mice treated with unconjugated, GalNAc-conjugated, or cholesterol-conjugated siRNAs and quantitatively assessed the biodistribution and activity of siRNAs in various organs. In addition, we used high-content imaging (HCI) and applied our multiplex siRNA immunoassay in tissue culture to enable simultaneous quantification of siRNA uptake, activity, and intracellular colocalization with endosome markers. These methods provide a robust platform for testing nucleic acid delivery methods in vitro and in vivo, allowing precise analysis and visualization of the pharmacokinetics and pharmacodynamics of siRNA therapeutics with cellular and subcellular resolution.
Collapse
Affiliation(s)
- Michael Ly
- Johnson & Johnson Innovative Medicine, La Jolla, California, USA
| | | | - Nathaniel Roscoe
- Johnson & Johnson Innovative Medicine, La Jolla, California, USA
| | - Irina Ushach
- Johnson & Johnson Innovative Medicine, La Jolla, California, USA
| | - Zhigang Hong
- Johnson & Johnson Innovative Medicine, Springhouse, Pennsylvania, USA
| | - Monique França
- Johnson & Johnson Innovative Medicine, La Jolla, California, USA
| | | | - Tong-Yuan Yang
- Johnson & Johnson Innovative Medicine, Springhouse, Pennsylvania, USA
| | - Mathieu Marella
- Johnson & Johnson Innovative Medicine, La Jolla, California, USA
| | - Glenn Marsboom
- Johnson & Johnson Innovative Medicine, Springhouse, Pennsylvania, USA
| | - Donna Klein
- Johnson & Johnson Innovative Medicine, Springhouse, Pennsylvania, USA
| | - Tamar R Grossman
- Johnson & Johnson Innovative Medicine, La Jolla, California, USA
| | | | - Michael Ollmann
- Johnson & Johnson Innovative Medicine, La Jolla, California, USA
| |
Collapse
|
3
|
Dunnington EL, Wong BS, Fu D. Innovative Approaches for Drug Discovery: Quantifying Drug Distribution and Response with Raman Imaging. Anal Chem 2024; 96:7926-7944. [PMID: 38625100 PMCID: PMC11108735 DOI: 10.1021/acs.analchem.4c01413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/17/2024]
Affiliation(s)
| | | | - Dan Fu
- Department of Chemistry, University of Washington, Seattle, WA, 98195, USA
| |
Collapse
|